Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Array Biopharma, Inc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (278)	4/22/2014 3:01:23 PM
From: mopgcw	Read Replies (2) \| Respond to of 321

Welcome aboard Rick. I have been holding a couple slugs since late '12 to watch this unfold. I should have taken the trade when she hit $7; but I think this is a very interesting long-term play. if it dips below 3 again, I will buy trading shares, but I think the platform will prove itself or go to 0. at least that is my theory. best. George

To: scaram(o)uche who wrote (278)	5/13/2014 6:05:06 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 321

Geeeeze, today was a TOUGH day to trade ASCO14. :-( >> My opinion (I'm not close to the situation, please get your own!) is that NVS loves MEK162, that it is imbedded in combo trials that would be difficult/expensive to duplicate using Mekinist, and that NVS will continue to develop it. << All sorts of indications today from Squarer at BofA/ML about how NVS' MEK162 decision is unknown to ARRY. Lots or assurance that, if returned, NVS will need to accompany it with plenty of funding. aside, regarding loxo-101.... loxooncology.com another company to watch at ASCO is Ignyta (rxdx), for results with their trk inhibitor.